Manuscript Topics

Antibodies are a natural product of the adaptive immune system that protects us against pathogenic agents. The first monoclonal antibody was approved by the US Food and Drug Administration (FDA) in 1986, and by 2022 more than 150 antibody therapies were approved. In the past decade the synergy of next-generation sequencing with antibody display platforms, transgenic animals, and single cell technologies have propelled the speed and scale of early-stage antibody discovery. Advanced in silico approaches such as rational optimization of developability, prediction of pharmaceutical properties, and even de novo molecule design, are transforming monoclonal antibodies into the next-generation antibody biologics, potentially with better therapeutic precision and potency. Many promising therapeutic modalities are now emerging, including antibody fragments, antibody-drug conjugates (ADC), T-cell engager antibodies, and multifunctional antibodies (bispecific/multispecific antibodies). By further harmonizing modern biotechnology and computational biology, innovative strategies using antibody biologics will continually push scientific boundaries and pave the way for personalized treatments in many disease areas.

We would like to invite authors to submit original research and/or review articles focused on the technology platforms, including computational methods, mechanisms of action, and therapeutic potential of novel monoclonal antibodies and antibody derivatives.

Instruction for Authors
http://www.aimspress.com/allergy/news/solo-detail/instructionsforauthors
Please submit your manuscript to online submission system
https://aimspress.jams.pub/